COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
27/07/2026
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight [...]
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
27/07/2026
Conference Call to Begin Today at 4:30 p.m. ET MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for [...]
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
27/07/2026
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed [...]
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
27/07/2026
CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports [...]
Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
27/07/2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, August 10, 2026, at 4:30 p.m. Eastern Time to report [...]
Quantum-Si to Report Second Quarter 2026 Financial Results on August 13, 2026
27/07/2026
BRANFORD, Conn., July 27, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule [...]
Nyxoah Publiera ses Résultats Financiers du Deuxième Trimestre 2026 le 5 août 2026
27/07/2026
Nyxoah Publiera ses Résultats Financiers du Deuxième Trimestre 2026 le 5 août 2026 Mont-Saint-Guibert, Belgique – 27 juillet 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « [...]
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
27/07/2026
Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), [...]
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
27/07/2026
Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and [...]
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
27/07/2026
DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET [...]
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
27/07/2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today provided an update ahead [...]
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
27/07/2026
Company announcement No. 35 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2026
27/07/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 20 juillet au 24 juillet 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026
27/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 20th July to 24th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
27/07/2026
Digital subscription platform brings together the Company’s proprietary consumer health products across consumer (B2C) and corporate (B2B) channels Customers can begin through one of three paths: a free nutritionist [...]
Atalante X, Wandercraft’s Self-Balancing Rehabilitation Exoskeleton, Receives ARCSA Clearance in Ecuador, Advancing Latin American Expansion
27/07/2026
Clearance broadens access to hands-free, overground robotic gait training in Ecuador, and supports Wandercraft’s plans to expand advanced rehabilitation technology across Latin America NEW YORK and QUITO, Ecuador, July [...]
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
27/07/2026
Exclusive partnership provides 319 Golf Society members with preferred Flyte benefits. FLYTE brings its regional luxury private aviation platform to members of premier private golf clubs across the United States FORT [...]
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
27/07/2026
Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance Corporation III’s (Nasdaq: RACC) (“RACC”) trust account that is fully backstopped [...]
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
27/07/2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, [...]

Pages